AIM
AIMT

Assured Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

Assured Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,525
Closed -$69K – 1395
2018
Q3 		$69K Buy
+2,525
New +$71.4K ﹤0.01% 1075

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Assured Investment Management's AIMT Position: Q4 2018 in Review

Assured Investment Management sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 2,525 shares — an estimated $69K sold.

Assured Investment Management first reported a position in AIMT in Q3 2018 and held it in 1 quarter. The position peaked at $69K in Q3 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • Assured Investment Management reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Assured Investment Management sold 2,525 Aimmune Therapeutics shares in Q4 2018, an estimated $69K.
  • Assured Investment Management first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 1 quarter.
  • Assured Investment Management's Aimmune Therapeutics position peaked at $69K in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on Assured Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.